Aardvark Therapeutics, Inc. Common Stock (AARD)

Aardvark Therapeutics, Inc. Common Stock (AARD) scores 34 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $0. Quantitative score: 52/100. Qualitative score: 20/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full AARD analysis on boothcheck